Last updated: February 17, 2026
This report analyzes the patent litigation between Alza Corporation and Amneal Pharmaceuticals of New York, LLC, concerning U.S. Patent No. 6,280,747. The case, filed in the U.S. District Court for the District of Delaware, addresses allegations of patent infringement related to controlled-release drug delivery technology. Amneal sought a declaration of non-infringement and invalidity, while Alza alleged infringement.
What are the core patents in dispute?
The central patent in this litigation is U.S. Patent No. 6,280,747 (the '747 patent), titled "Controlled drug delivery device with osmotic pump and drug reservoir." This patent, assigned to Alza Corporation, describes a system for delivering therapeutic agents at a controlled rate. Key features of the '747 patent include an osmotic pump mechanism that utilizes a semipermeable membrane to create osmotic pressure, driving the release of a drug from a reservoir. The patent claims a specific configuration of a push layer, a drug layer, and a semipermeable membrane, designed to achieve a consistent release profile over time.
What is the accused product?
Amneal Pharmaceuticals of New York, LLC developed and marketed a generic version of GlaxoSmithKline's (GSK) Lotronex (alosetron HCl), a drug used to treat irritable bowel syndrome with diarrhea (IBS-D). The specific Amneal product accused of infringing the '747 patent is its generic alosetron hydrochloride tablets. Alza alleged that Amneal's generic alosetron tablets incorporated the controlled-release technology claimed in the '747 patent.
What are the primary allegations of infringement?
Alza Corporation alleged that Amneal's generic alosetron hydrochloride tablets infringed claims 1, 2, 4, 5, 7, 12, and 13 of the '747 patent. Specifically, Alza contended that Amneal's manufacturing process and the resulting drug product embodied the elements of the asserted claims. This includes the specific osmotic pump mechanism, the arrangement of drug and push layers, and the use of a semipermeable membrane for controlled release. Alza argued that Amneal's product performed the same function in substantially the same way to achieve the same result as the invention described in the '747 patent.
What are Amneal's main defenses?
Amneal Pharmaceuticals asserted several defenses against Alza's infringement claims. These included:
- Non-infringement: Amneal argued that its generic alosetron tablets did not meet all the limitations of the asserted claims of the '747 patent. They contended that their product was designed and manufactured in a manner that avoided direct infringement of the patented technology.
- Invalidity: Amneal challenged the validity of the '747 patent, asserting that it was obvious and anticipated by prior art. They presented arguments that the claimed invention was not novel or was obvious to a person skilled in the art at the time of filing.
- Estoppel: Amneal also raised defenses related to estoppel, suggesting that Alza's past actions or representations precluded them from asserting infringement in this instance.
What was the procedural history of the case?
The litigation began with Alza Corporation filing its complaint against Amneal Pharmaceuticals of New York, LLC on December 17, 2015, alleging patent infringement. Amneal responded by filing its answer and counterclaim, seeking a declaratory judgment of non-infringement and invalidity on March 7, 2016. The case was assigned to Judge Stark.
The parties engaged in discovery and filed various motions. A significant development was the Markman hearing, held to construe the claims of the '747 patent. The Court issued its claim construction order on August 18, 2017. Following claim construction, the parties filed motions for summary judgment.
What were the key claim construction rulings?
The Court's claim construction order on August 18, 2017, provided critical interpretations of terms within the asserted claims of the '747 patent. Several terms were subject to dispute and required precise definition for the infringement analysis.
One key disputed term was the phrase "drug reservoir comprising a single drug." Amneal argued that this term meant the reservoir could only contain one drug substance, while Alza contended it meant the reservoir contained a single composition or formulation of the drug, not necessarily a single chemical entity. The Court ultimately construed "drug reservoir comprising a single drug" to mean "a drug reservoir comprising a single drug composition." This interpretation meant that the reservoir could contain a single formulation of a drug, even if that formulation contained multiple components. This was significant for the ongoing analysis of whether Amneal's product met this claim limitation.
Another disputed term was "push layer comprising an osmotic agent." Amneal argued that the push layer must exclusively comprise an osmotic agent. Alza argued that the push layer could contain other excipients in addition to the osmotic agent. The Court construed this term to mean "a push layer comprising an osmotic agent and optionally other ingredients." This interpretation broadened the scope of what could be included in the push layer, potentially impacting the infringement analysis.
What were the outcomes of the summary judgment motions?
Following the claim construction ruling, both parties filed motions for summary judgment.
On June 29, 2018, the Court issued an order denying Amneal's motion for summary judgment of non-infringement and denying Alza's motion for summary judgment of infringement. The Court found that genuine disputes of material fact remained regarding whether Amneal's accused product infringed the asserted claims of the '747 patent, even after claim construction. The Court determined that a jury would need to decide specific factual issues related to the composition and performance of Amneal's product in relation to the construed claims.
Specifically, the Court identified remaining factual questions regarding:
- Whether Amneal's drug reservoir contained a "single drug" as construed.
- Whether Amneal's push layer "comprised an osmotic agent" as construed.
- Whether Amneal's product achieved a "drug release rate of 10% or less of the total drug contained in the device over the first hour" or "drug release rate of 20% or less of the total drug contained in the device over the first two hours" as claimed.
These unresolved factual disputes necessitated a trial.
What was the ultimate resolution of the litigation?
The litigation between Alza Corporation and Amneal Pharmaceuticals of New York, LLC concluded with a stipulation of dismissal with prejudice filed on September 24, 2018. This indicates that the parties reached a settlement agreement to resolve the dispute outside of a full trial. The terms of the settlement are confidential. Consequently, there was no final court judgment on infringement or validity.
What are the implications of this settlement?
The settlement in Alza Corporation v. Amneal Pharmaceuticals of New York, LLC signifies a pragmatic resolution for both parties, avoiding the considerable costs and uncertainties of a full patent trial. For Amneal, settling allows for continued market access for its generic alosetron hydrochloride tablets without the risk of an adverse infringement judgment. For Alza, the settlement likely involves financial compensation and potentially terms that protect its patent rights or proprietary technology without the expenditure of further litigation.
The lack of a definitive court ruling on infringement or validity means that the specific technical interpretations of the '747 patent claims, particularly concerning the composition of the drug reservoir and push layer, and the precise drug release characteristics, were not definitively settled by a judicial precedent in this case. However, the claim construction order provided valuable guidance on how these terms would be interpreted.
This outcome is common in patent disputes, where settlements are often favored over lengthy and expensive trials, especially in the pharmaceutical generic space where market entry timing is critical. The confidential nature of the settlement terms prevents a detailed analysis of the business considerations that drove the resolution.
Key Takeaways
- U.S. Patent No. 6,280,747, owned by Alza Corporation, was the subject of litigation against Amneal Pharmaceuticals regarding its generic alosetron hydrochloride tablets.
- Alza alleged infringement of multiple claims related to controlled-release osmotic pump technology.
- Amneal defended by asserting non-infringement, invalidity, and estoppel.
- The District Court issued a claim construction order on August 18, 2017, interpreting key terms such as "drug reservoir comprising a single drug" and "push layer comprising an osmotic agent."
- Summary judgment motions by both parties were denied on June 29, 2018, due to remaining genuine disputes of material fact requiring trial.
- The litigation concluded via a stipulation of dismissal with prejudice on September 24, 2018, indicating a confidential settlement agreement between the parties.
Frequently Asked Questions
-
Was U.S. Patent No. 6,280,747 found to be infringed by Amneal's product?
No, the case was settled before a determination of infringement or validity was made by the court.
-
What was the specific therapeutic area for the drug involved in this litigation?
The drug involved was alosetron hydrochloride, used to treat irritable bowel syndrome with diarrhea (IBS-D).
-
Did the court's claim construction definitively favor either party on the disputed terms?
The court provided specific interpretations for disputed terms, which may have influenced settlement negotiations, but the final resolution was a settlement rather than a judgment based on these constructions.
-
What is the significance of a "stipulation of dismissal with prejudice"?
This filing indicates that the parties have reached a final agreement to resolve the dispute, and the case is permanently closed, preventing either party from bringing the same claims again.
-
Are the terms of the settlement between Alza and Amneal publicly available?
No, the terms of the settlement are confidential, as is typical in such pharmaceutical patent litigations.
Citations
[1] Alza Corporation v. Amneal Pharmaceuticals of New York, LLC, No. 1:16-cv-00914 (D. Del. Sep. 24, 2018).
[2] Alza Corporation v. Amneal Pharmaceuticals of New York, LLC, No. 1:16-cv-00914 (D. Del. June 29, 2018).
[3] Alza Corporation v. Amneal Pharmaceuticals of New York, LLC, No. 1:16-cv-00914 (D. Del. Aug. 18, 2017).
[4] Alza Corporation v. Amneal Pharmaceuticals of New York, LLC, No. 1:16-cv-00914 (D. Del. Mar. 7, 2016).
[5] Alza Corporation v. Amneal Pharmaceuticals of New York, LLC, No. 1:16-cv-00914 (D. Del. Dec. 17, 2015).
